704 related articles for article (PubMed ID: 12671459)
1. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
2. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
3. The future of respiratory syncytial virus vaccine development.
Polack FP; Karron RA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
[TBL] [Abstract][Full Text] [Related]
4. Human and bovine respiratory syncytial virus vaccine research and development.
Meyer G; Deplanche M; Schelcher F
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):191-225. PubMed ID: 17720245
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
Venkatesh MP; Weisman LE
Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
[TBL] [Abstract][Full Text] [Related]
6. Prevention strategies for respiratory syncytial virus: passive and active immunization.
Englund JA
J Pediatr; 1999 Aug; 135(2 Pt 2):38-44. PubMed ID: 10431138
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
Wright PF; Karron RA; Belshe RB; Thompson J; Crowe JE; Boyce TG; Halburnt LL; Reed GW; Whitehead SS; Anderson EL; Wittek AE; Casey R; Eichelberger M; Thumar B; Randolph VB; Udem SA; Chanock RM; Murphy BR
J Infect Dis; 2000 Nov; 182(5):1331-42. PubMed ID: 11010838
[TBL] [Abstract][Full Text] [Related]
8. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
9. Advances in respiratory syncytial virus vaccine development.
Kneyber MC; Kimpen JL
Curr Opin Investig Drugs; 2004 Feb; 5(2):163-70. PubMed ID: 15043390
[TBL] [Abstract][Full Text] [Related]
10. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
Johnson TR; Graham BS
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
[TBL] [Abstract][Full Text] [Related]
11. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
Durbin AP; Karron RA
Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
[TBL] [Abstract][Full Text] [Related]
12. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
Harcourt JL; Karron RA; Tripp RA
J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
[TBL] [Abstract][Full Text] [Related]
13. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
Cabalka AK
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
[TBL] [Abstract][Full Text] [Related]
14. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus infection in adults.
Falsey AR
Semin Respir Crit Care Med; 2007 Apr; 28(2):171-81. PubMed ID: 17458771
[TBL] [Abstract][Full Text] [Related]
16. [Respiratory syncytial virus: as an etiological agent of respiratory tract infection in children and adults].
Belino-Studzińska P; Pancer K
Przegl Epidemiol; 2008; 62(4):767-75. PubMed ID: 19209739
[TBL] [Abstract][Full Text] [Related]
17. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
18. Basic epidemiology and immunopathology of RSV in children.
Handforth J; Friedland JS; Sharland M
Paediatr Respir Rev; 2000 Sep; 1(3):210-4. PubMed ID: 12531081
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus: A continuing culprit and conundrum.
Hall CB
J Pediatr; 1999 Aug; 135(2 Pt 2):2-7. PubMed ID: 10431132
[TBL] [Abstract][Full Text] [Related]
20. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
